Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

* INCLUSION CRITERIA:
* Adults over the age of 60
* Documentation of positive diagnosis for any of the following:

  * Non metastatic breast carcinoma following neo-adjuvant chemotherapy and appropriate surgery or following adjuvant radio / chemotherapy.
  * Stage II or III colon carcinoma following appropriate surgery and adjuvant chemotherapy or following appropriate neoadjuvant chemoradiation/surgery and adjuvant chemotherapy.
  * Stage II bladder carcinoma following neo-adjuvant chemotherapy and appropriate surgery or following adjuvant chemotherapy. Patients with recurrent tumors are not eligible.
  * Appropriate therapy for each disease must be consistent with the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology available at the web site: http://www.nccn.org/professionals/physician\_gls/f\_guidelines.asp
  * Completed cancer specific therapy (including surgery, radiotherapy and/or chemotherapy) a minimum of 4 weeks prior to entry. (Subjects with hormone receptor positive breast carcinoma maintained on hormonal therapy following chemotherapy and radiation are eligible).
* Completed cancer specific therapy at most 6 months prior to entry.
* Reasonable expectation that no chemotherapy will be given in the subsequent 6 months (Principal Investigators (PIs) discretion).
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times the upper limit of normal.
* Bilirubin \< 1.5.
* Absolute Neutrophil Count greater than l000 / mm(3).
* Platelet count greater than 75K.
* International normalized ratio (INR)/partial thromboplastin time (PTT) within 1.5 times upper limit of normal (Common Terminology Criteria in Adverse Events (CTCAE) 4.0 grade 1 abnormality is acceptable)
* Serum creatinine within 1.5 times upper limit of normal (CTCAE 4.0 grade 1 abnormality is acceptable)
* Creatine phosphokinase (CPK) within 2.5 times upper limit of normal (CTCAE 4.0 grade 1 abnormality is acceptable)
* Serum albumin greater or equal to 3g/dl (CTCAE 4.0 grade 1 abnormality is acceptable)
* Serum electrolytes within normal limits (CTCAE 4.0 grade 1 abnormality is acceptable)
* Karnofsky performance status greater or equal to 70%.

EXCLUSION CRITERIA FOR ALL PARTICIPANTS:

* Significant heart disease defined as:

  * Significant coronary arterial disease
  * myocardial infarction in the last 6 months, angina in the previous 3 months,
  * Troponin elevation at level of myocardial infarction as defined by the manufacturer
  * Ischemic changes on electrocardiogram (ECG)
  * Atrio-ventricular block greater than 1st degree, in absence of pacemaker,
  * Corrected QT interval (QTc) greater than 480ms (CTCAE 4.0 grade 1 abnormality is acceptable),
  * History of ventricular arrhythmia,
  * Left Ventricular Ejection Fraction below the institutional limit of normal,
* Positive serology for human T-lymphotropic viruses, type 1 (HTLV I), human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection including a positive hepatitis B serology indicative of previous immunization (i.e. hepatitis B surface antibody (HBs Ab) positive and hepatitis B core antibody (HBc Ab) negative)
* History of autoimmune disease: patients with vitiligo or endocrine disease controlled by replacement therapy including, diabetes, thyroid and adrenal disease may be enrolled
* Patients requiring chronic immunosuppressive therapy (including corticosteroids) for any medical condition,
* Splenomegaly or history of proliferative hematologic disease
* Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation
* Inability or refusal to practice contraception during therapy (as physiologically relevant)
* History of medical or psychiatric disease which, in the view of the principal investigator, would preclude safe treatment
* Cognitive impairment
* Serious bleeding diathesis or those who are on therapeutic anticoagulation
* Previous exposure to Hepatitis A or B vaccines

Patients who received a tetanus and diphtheria (Td) or tetanus, diphtheria- acelluar, pertussis (Tdap) immunization in the previous 5 years,

* History of anaphylaxis or serious allergic reactions to previous administration of any of the vaccines
* Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymixin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast
* Patients who had received one or more doses of the pneumococcal polysaccharide vaccine 23 (PPSV23) vaccine in the previous 12 months
* Inability to give informed consent